BRIEF published on 09/08/2025 at 22:05, 6 months 14 days ago Abivax publie ses résultats financiers du premier semestre 2025 Résultats Financiers Obligations Convertibles Recherche Et Développement Offre Publique Réserves De Trésorerie
PRESS RELEASE published on 09/08/2025 at 22:00, 6 months 14 days ago Abivax présente ses résultats financiers du premier semestre 2025 Abivax présente ses résultats financiers du premier semestre 2025, avec une perte nette de 100,8 millions d'euros. Principalement axée sur le développement de thérapies pour les maladies inflammatoires Résultats Financiers Abivax Perte Nette Thérapies Premier Semestre 2025
PRESS RELEASE published on 09/08/2025 at 22:00, 6 months 14 days ago Abivax Presents First Half 2025 Financial Results Abivax presents first half 2025 financial results, revealing operating loss increase and net loss for the period, also updates on clinical programs and public offering Financial Results Abivax Public Offering Clinical Programs Operating Loss
BRIEF published on 09/02/2025 at 11:00, 6 months 20 days ago JP Morgan Chase & Co. Crosses Threshold at ABIVAX Voting Rights Capital Abivax Threshold Crossing JP Morgan
BRIEF published on 09/02/2025 at 11:00, 6 months 20 days ago Franchissement de seuil par J.P. Morgan Chase & Co. chez ABIVAX Capital Droits De Vote Franchissement De Seuil Abivax J.P. Morgan
PRESS RELEASE published on 09/02/2025 at 10:55, 6 months 20 days ago Franchissement de seuil Déclaration de franchissement de seuil de 5% du capital de la société ABIVAX par la société J.P. Morgan Chase & Co. indirectement, le 28 août 2025 Déclaration Franchissement De Seuil Abivax 5% J.P. Morgan Chase
BRIEF published on 08/13/2025 at 18:05, 7 months 9 days ago ABIVAX : Mise à jour sur le capital et les droits de vote Euronext Paris Droits De Vote Capital Social AMF Abivax
BRIEF published on 08/13/2025 at 18:05, 7 months 9 days ago ABIVAX: Update on capital and voting rights Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF published on 08/13/2025 at 18:05, 7 months 9 days ago ABIVAX: Share and voting rights data as of July 31, 2025 Euronext Paris Voting Rights Biotechnology Actions AMF Regulations
BRIEF published on 08/13/2025 at 18:05, 7 months 9 days ago ABIVAX: Données sur les actions et droits de vote au 31 juillet 2025 Euronext Paris Droits De Vote Biotechnologie Actions Réglementation AMF
Published on 03/23/2026 at 08:00, 2 hours 22 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 8 hours 22 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 09:19, 1 hour 3 minutes ago Mister Spex Chooses Salesforce to further develop its Omnichannel Strategy
Published on 03/23/2026 at 09:00, 1 hour 22 minutes ago EQS Group launches Risk Management module to support continuous data and AI risk oversight
Published on 03/23/2026 at 08:10, 2 hours 12 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
